Matthew J. O'Brien

Dr. Matthew J. O'Brien

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
GXGuifeng Xu
Guifeng Xu
Lane StrathearnLane Strathearn
Lane Strathearn
BLBuyun Liu
Buyun Liu
MOMatthew J. O'Brien
Matthew J. O'Brien
TKTodd G. Kopelman
Todd G. Kopelman
WBWei Bao
Wei Bao
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by repetitive behaviors and restricted interests, social impairments, and communication difficulties.1 The etiology of ASD remains to be understood, but it likely involves a complex interplay of genetic and environmental factors.2,3 So far, there is no cure for ASD, and children with ASD need long-term and ongoing treatment and care. Autism spectrum disorder not only results in significant caregiving burden for individuals, families, and society but also causes substantial economic costs.4 In the United States, estimates for ASD-related individual lifetime costs were on average $1.4 million among individuals with an ASD without intellectual disability and $2.4 million among individuals with an ASD with intellectual disability.5

1 December 2020 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
SLScott Lindgren
Scott Lindgren
DWDavid Wacker
David Wacker
KSKelly Schieltz
Kelly Schieltz
ASAlyssa Suess
Alyssa Suess
KPKelly Pelzel
Kelly Pelzel
MOMatthew J. O'Brien
Matthew J. O'Brien

4 December 2023 in Journal of Applied Behavior Analysis
Verified
Journal Article
Closed access
NCNathan A. Call
Nathan A. Call
ABAlec M. Bernstein
Alec M. Bernstein
MOMatthew J. O'Brien
Matthew J. O'Brien
KSKelly Schieltz
Kelly Schieltz
LTLoukia Tsami
Loukia Tsami
DWDavid P. Wacker
David P. Wacker

24 January 2023 in Frontiers in Neuroimaging
Verified
Journal Article
Open access
EPEva Poliakova
Eva Poliakova
ACAmy L. Conrad
Amy L. Conrad
KSKelly M. Schieltz
Kelly M. Schieltz
MOMatthew J. O'Brien
Matthew J. O'Brien
Background: Functional near infrared spectroscopy (fNIRS) is a relatively non-invasive and inexpensive functional neuroimaging technique that has shown promise as a method for understanding the differences in neuronal activity associated with various neurodevelopmental conditions, including ADHD. Additionally, fNIRS has been suggested as a possible tool to understand the impact of psychotropic medications on brain activity in individuals with ADHD, but this approach is still in its infancy.Objective: The purpose of this systematic literature review was to synthesize the extant research literature on the use of fNIRS to assess the effects of ADHD medications on brain activity in children and adolescents with ADHD.Methods: A literature search following Preferred Reporting Items for Systematic Literature Reviews and Meta-Analyses (PRISMA) guidelines was conducted for peer-reviewed articles related to ADHD, medication, and fNIRS in PsychInfo, Scopus, and PubMed electronic databases.Results: The search yielded 23 published studies meeting inclusion criteria. There was a high degree of heterogeneity in terms of the research methodology and procedures, which is explained in part by the distinct goals and approaches of the studies reviewed. However, there was also relative consistency in outcomes among a select group of studies that demonstrated a similar research focus.Conclusion: Although fNIRS has great potential to further our understanding of the effects of ADHD medications on the neuronal activity of children and adolescents with ADHD, the current research base is still relatively small and there are limitations and methodological inconsistencies that should be addressed in future studies.

13 April 2024 in The Journal of Pediatrics
Verified
Journal Article
Open access
MOMatthew J. O'Brien
Matthew J. O'Brien
APAlexander M. Pauls
Alexander M. Pauls
ACAnna M. Cates
Anna M. Cates
PLPriya D. Larson
Priya D. Larson
AZAlithea N. Zorn
Alithea N. Zorn
To evaluate the prevalence, trends, and factors associated with psychotropic medication use and polypharmacy among children and adolescents initiating intensive behavioral therapy for severe challenging behavior over a 10-year period. In this retrospective observational study, we examined data from caregiver interviews and patient medical records on the number and types of psychotropic medications prescribed to patients initiating intensive behavioral therapy between January 1, 2013, and December 31, 2022. Trends in medication use and polypharmacy across the 10-year period were analyzed using regression analysis, while differences in demographics and clinical factors for patients with use and polypharmacy were analyzed using nonparametric statistical analysis with odds ratios presented for significant factors. Data from all 302 pediatric patients initiating intensive behavioral therapy across the 10-year period were analyzed. Among all patients and all years, 83.8% were taking at least 1 psychotropic medication and 68.2% experienced polypharmacy. There were no changes in the prevalence of use, mean number of medications taken, or polypharmacy across the 10-year period. Patients diagnosed with attention-deficit/hyperactivity disorder or anxiety disorder, as well as those exhibiting self-injurious behavior had higher use of psychotropic medication and polypharmacy and were taking more medications overall. Psychotropic medication use and polypharmacy were extremely high for children and adolescents with severe challenging behavior, but use and polypharmacy did not change over the 10-year period of data collection. Further research is needed to establish the generality of these findings to other regions of the US.

24 December 2020 in Research and Practice for Persons With Severe Disabilities
Verified
Journal Article
Closed access
PDF file
MOMatthew J. O'Brien
Matthew J. O'Brien
KSKelly Schieltz
Kelly Schieltz
WBWendy K. Berg
Wendy K. Berg
JMJennifer J. McComas
Jennifer J. McComas
DWDavid P. Wacker
David P. Wacker
In this article, we provide a case example of how telehealth can be used by care providers in their homes to access empirically validated procedures such as functional communication training. As shown in the case example, complex assessment and intervention procedures were implemented successfully by care providers in their homes while receiving real-time coaching by behavior analysts who were located in a hospital in a different city. This case example is representative of the results we obtained thus far; substantial improvements in challenging and adaptive behavior occurred. Given these results obtained to date with telehealth, in terms of both outcomes of interventions and rated acceptability of the procedures by care providers, further and more widespread application of telehealth is warranted.